IFNB1 and myeloid sarcoma: As currently known, DMT in MS include agents from low to moderate therapeutic efficiency, as well as less risk for a scenario that favors infection by the new coronavirus, such as glatirameracetate, interferons beta, teriflunomide, and dimethylfumarate.